|

Restoring Cervical Lymphatic Drainage in Alzheimer's Disease

RECRUITINGN/ASponsored by University of Siena
Actively Recruiting
PhaseN/A
SponsorUniversity of Siena
Started2026-07-01
Est. completion2028-07-01
Eligibility
Healthy vol.Accepted

Summary

Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with the accumulation of abnormal proteins, including amyloid-beta and tau, in the brain. Recent evidence suggests that the glymphatic and meningeal lymphatic systems, which contribute to the removal of waste products from the brain, may play a role in AD. In particular, impaired drainage through the deep cervical lymphatic system may contribute to the accumulation of disease-related proteins. The LymphDAD study is a prospective, single-center pilot study designed to explore whether surgically improving cervical lymphatic drainage may be associated with changes in biological markers, brain imaging, and cognitive and clinical measures in selected patients with AD who are not eligible for currently available disease-modifying treatments. Five participants with AD will undergo a minimally invasive microsurgical procedure called lymphovenous anastomosis (LVA), in which small cervical lymphatic vessels are connected to nearby small veins to facilitate lymphatic drainage. During the procedure, a small sample of lymphatic fluid will also be collected for exploratory analysis of amyloid-beta and tau proteins. Participants will undergo clinical and neuropsychological assessments, blood sampling, magnetic resonance imaging (MRI), and amyloid positron emission tomography (PET) before the procedure and during follow-up. Follow-up assessments will be performed at 1, 3, 6, and 12 months after surgery. The study is exploratory and is not designed to demonstrate a definitive clinical benefit. Its primary purpose is to obtain preliminary information on the feasibility, safety, and possible biological and clinical effects of cervical LVA in AD, which may support the design of future controlled studies.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Diagnosis of Alzheimer's disease according to NIA-AA 2024 criteria.
* Not eligible for other disease-modifying therapies.
* Ability to personally provide written informed consent after clinical evaluation -of decisional capacity.

Exclusion Criteria:

* Coagulopathy or active infection of the head and neck region.
* Prior extensive cervical lymph node dissection or radiotherapy.
* Uncontrolled systemic disease or contraindication to general anesthesia.
* Participation in another interventional trial within the previous 3 months.
* Known hypersensitivity or allergy to indocyanine green.
* Evidence of alternative or concomitant causes of cognitive decline other than Alzheimer's disease, such as subdural hematoma, primary or metastatic brain malignancy, or normal-pressure hydrocephalus.
* Current or recent treatment with immunosuppressive or immunomodulatory therapy within the previous 3 months.
* Clinically significant infectious disease within the previous 6 months.
* Severe psychiatric disorder that could interfere with cognitive assessment or study participation.
* Pregnancy or breastfeeding.
* End-stage malignant disease with an estimated life expectancy of less than 6 months.
* History indicative of systemic autoimmune disease.
* Inability to personally provide valid informed consent.

Conditions3

AlzheimerAlzheimer Dementia (AD)Alzheimer's Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.